Connection

Daniel Judge to Amyloid Neuropathies, Familial

This is a "connection" page, showing publications Daniel Judge has written about Amyloid Neuropathies, Familial.
Connection Strength

5.908
  1. ATTR Epidemiology, Genetics, and Prognostic Factors. Methodist Debakey Cardiovasc J. 2022; 18(2):17-26.
    View in: PubMed
    Score: 0.832
  2. Wild-Type Transthyretin Cardiac Amyloidosis Is Associated with Increased Antecedent Physical Activity. J Cardiovasc Transl Res. 2022 08; 15(4):689-691.
    View in: PubMed
    Score: 0.824
  3. Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR). Cardiovasc Drugs Ther. 2020 06; 34(3):357-370.
    View in: PubMed
    Score: 0.735
  4. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid?Cardiomyopathy. J Am Coll Cardiol. 2019 07 23; 74(3):285-295.
    View in: PubMed
    Score: 0.676
  5. Positive family history decreases diagnosis time by over 200. Amyloid. 2019; 26(sup1):17.
    View in: PubMed
    Score: 0.666
  6. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Amyloid. 2017 Jun; 24(2):92-95.
    View in: PubMed
    Score: 0.595
  7. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT. ESC Heart Fail. 2021 10; 8(5):3875-3884.
    View in: PubMed
    Score: 0.200
  8. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021 02; 23(2):277-285.
    View in: PubMed
    Score: 0.190
  9. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13; 379(11):1007-1016.
    View in: PubMed
    Score: 0.163
  10. Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid. 2017 Sep; 24(3):194-204.
    View in: PubMed
    Score: 0.151
  11. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy. Ann Neurol. 2017 Jul; 82(1):44-56.
    View in: PubMed
    Score: 0.150
  12. Untangling Wild-Type Transthyretin?Amyloidosis. J Am Coll Cardiol. 2016 09 06; 68(10):1021-3.
    View in: PubMed
    Score: 0.142
  13. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 07 12; 68(2):161-72.
    View in: PubMed
    Score: 0.140
  14. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015 May; 8(3):519-26.
    View in: PubMed
    Score: 0.129
  15. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015 Mar; 8(2):117-27.
    View in: PubMed
    Score: 0.128
  16. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013 Dec; 6(6):1011-20.
    View in: PubMed
    Score: 0.116
  17. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid. 2018 Sep; 25(3):174-179.
    View in: PubMed
    Score: 0.041
  18. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. J Cardiovasc Transl Res. 2015 Jun; 8(4):264-8.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.